Retatrutide (LY3437943)

Mechanism of Action

Retatrutide (LY3437943) is a first-in-class single-molecule triple agonist that simultaneously activates three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This triple agonism distinguishes retatrutide from dual agonists such as tirzepatide (GIP/GLP-1) and from single GLP-1 receptor agonists such as semaglutide.1 The molecule is engineered as a 39-amino acid peptide with a C-20 fatty diacid moiety that enables albumin binding and extends the plasma half-life to approximately 6 days, permitting once-weekly subcutaneous dosing.2

The GLP-1 receptor agonist component drives the established incretin effects: glucose-dependent potentiation of insulin secretion from pancreatic beta cells, suppression of inappropriately elevated glucagon from alpha cells, delayed gastric emptying, and central appetite suppression via hypothalamic GLP-1 receptor activation.13 The GIP receptor agonist component provides complementary and synergistic effects on energy balance, including potentiation of central appetite suppression (GIP receptors are expressed in the hypothalamus), enhanced insulin secretion, and potential direct effects on adipose tissue metabolism.3

The glucagon receptor agonist component is the novel element that differentiates retatrutide from all other incretin-based therapies. Glucagon receptor activation increases energy expenditure through hepatic thermogenesis, promotes hepatic lipid oxidation and ketogenesis, and stimulates amino acid catabolism. In preclinical models, the glucagon component contributed to increased resting energy expenditure of 5–10%, thereby enhancing the caloric deficit beyond what is achievable through appetite suppression alone.14 This dual mechanism of reduced energy intake (via GLP-1 and GIP) combined with increased energy expenditure (via glucagon) provides a theoretical basis for the unprecedented weight-loss efficacy observed in Phase 2 trials. Importantly, the potential hyperglycemic effect of glucagon receptor activation is counterbalanced by the concurrent GLP-1 and GIP receptor agonism, resulting in net improved glycemic control.2

Evidence Summary

Phase 2 Obesity Trial (Jastreboff et al., NEJM 2023)

The pivotal Phase 2 dose-finding trial randomized 338 adults with obesity (BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity) without diabetes to receive subcutaneous retatrutide (1 mg, 4 mg initial/4 mg maintenance, 4 mg initial/8 mg maintenance, 4 mg initial/12 mg maintenance) or placebo weekly for 48 weeks.1 Results demonstrated dose-dependent weight loss of extraordinary magnitude: participants receiving the 12 mg dose achieved a mean body weight reduction of 24.2% from baseline at 48 weeks, compared with 2.1% for placebo (treatment difference −22.1 percentage points; p<0.001).1 At the 12 mg dose, 100% of participants lost at least 5% of body weight, 93% lost at least 10%, 83% lost at least 15%, and 63% lost at least 20%.1 The weight-loss trajectory had not plateaued at 48 weeks, suggesting even greater reductions with longer treatment duration.

Phase 2 Type 2 Diabetes Trial (Rosenstock et al., NEJM 2023)

A parallel Phase 2 trial randomized 281 adults with type 2 diabetes (HbA1c 7.0–10.5%) to retatrutide (0.5 mg, 4 mg titrated to 4 mg, 4 mg titrated to 8 mg, 4 mg titrated to 12 mg) or placebo weekly for 36 weeks.2 At the 12 mg dose, mean HbA1c reduction from baseline was −2.02% (vs −0.01% with placebo), with 71% of participants achieving HbA1c <5.7% (normoglycemia). Body weight reduction was −16.94% at 12 mg at 36 weeks in the diabetic population.2 These results compare favorably with the leading dual agonist tirzepatide, which achieved approximately 12–15% weight loss in comparable diabetic populations.

Phase 3 Program (TRIUMPH)

The TRIUMPH (Triple Hormone Receptor Agonist in the Metabolic Platform of Health) Phase 3 clinical program was initiated in 2023–2024 and comprises multiple large-scale, randomized, double-blind trials evaluating retatrutide for obesity and type 2 diabetes. Key trials include TRIUMPH-1 (obesity without diabetes), TRIUMPH-2 (type 2 diabetes), and TRIUMPH-3 (obesity with specific comorbidities). Results from the Phase 3 program are expected to read out during 2025–2026, and if positive, would support a regulatory filing with the FDA.5

NAFLD / MASLD Signal

Exploratory analyses from the Phase 2 trials demonstrated significant reductions in hepatic fat content. In a sub-study using MRI-proton density fat fraction (MRI-PDFF), retatrutide 12 mg reduced liver fat by approximately 82–86% at 48 weeks, with the majority of participants achieving normalization of liver fat content (<5% PDFF). This finding is consistent with the anticipated effects of glucagon receptor agonism on hepatic lipid metabolism and has prompted dedicated investigation of retatrutide for metabolic dysfunction-associated steatotic liver disease (MASLD).4

Primary Uses

• Chronic weight management (investigational): Retatrutide is under Phase 3 investigation for adults with obesity (BMI ≥30 kg/m²) or overweight with comorbidities (BMI ≥27 kg/m²). Phase 2 data demonstrated up to 24.2% weight loss at 48 weeks.1
• Type 2 diabetes mellitus (investigational): Phase 2 data demonstrated HbA1c reductions of up to 2.02% and body weight reductions of up to 16.94% in patients with T2D.2
• Metabolic dysfunction-associated steatotic liver disease (investigational): Exploratory data showed dramatic reductions in hepatic fat. Dedicated MASLD/MASH trials are under consideration.4

Common Stacks & Synergies

As an investigational compound, retatrutide has been studied primarily as monotherapy or with limited background medications. The following combination approaches have been explored in clinical trials or are theoretically relevant:

• Metformin + Retatrutide (T2D trials): In the Phase 2 diabetes trial, metformin was permitted as background therapy. The combination of retatrutide's triple agonism with metformin's hepatic glucose output suppression and insulin sensitization is complementary.2
• Structured lifestyle intervention + Retatrutide: All Phase 2 trial participants received counseling on diet and physical activity. The combination of pharmacotherapy with behavioral intervention is expected to optimize outcomes, although the magnitude of weight loss with retatrutide may exceed what lifestyle intervention alone can achieve.1
• Resistance training (theoretical): Given the substantial weight loss observed, preservation of lean body mass through resistance exercise programming may be particularly important with retatrutide therapy. This has not been formally studied in dedicated trials.

For detailed combination protocols and titration schedules, see our Protocols page.

Preparation & Administration

Subcutaneous Injection (Clinical Trial Formulation)

In Phase 2 clinical trials, retatrutide was administered as a once-weekly subcutaneous injection. The exact commercial formulation and delivery device have not been finalized. The following information is based on the Phase 2 trial protocols:

• Injection sites: Abdomen, thigh, or upper arm. Rotation of injection sites with each dose was required per clinical trial protocol.
• Timing: Once weekly on the same day each week, at any time of day, with or without meals.
• Dose escalation: All dose groups ≥4 mg underwent a stepwise titration from 2 mg starting dose, with 4-week intervals between dose increases, to minimize gastrointestinal tolerability issues.1
• Formulation details: The commercial formulation (pen device, concentration, excipients) has not been publicly disclosed as of April 2026. Clinical trial supply was provided by Eli Lilly.

For general subcutaneous injection technique guidance, see our Injection Safety guide.

Side Effects & Adverse Events

Common Adverse Reactions (Phase 2 Data)

The adverse event profile of retatrutide in Phase 2 trials was broadly consistent with the GLP-1 receptor agonist class, with gastrointestinal events being the most common. Rates were dose-dependent and most events occurred during dose escalation.12

• Nausea: 16–45% (dose-dependent; highest in the 12 mg group)
• Diarrhea: 14–33%
• Vomiting: 6–23%
• Constipation: 6–16%
• Dyspepsia / abdominal pain: 4–14%
• Decreased appetite: 10–22%
• Injection site reactions: 2–5%

Discontinuation due to adverse events occurred in approximately 6% of participants in the 12 mg obesity group, compared with 4% in the placebo group.1

Adverse Events of Special Interest

• Heart rate increase: Mean increases of 2–4 bpm were observed across dose groups, consistent with the GLP-1 agonist class. Clinical significance is uncertain and will be further evaluated in Phase 3.1
• Pancreatitis: No cases of adjudicated pancreatitis were reported in Phase 2 trials, but the sample size was insufficient to detect rare events.1
• Gallbladder events: Cholelithiasis was reported in a small number of participants. Rapid weight loss of this magnitude independently increases gallstone risk.
• Hepatic effects: ALT elevations were observed in some participants, though the clinical significance is difficult to interpret given the concurrent dramatic reduction in hepatic steatosis. No cases of drug-induced liver injury were reported.4
• Thyroid C-cell concern: As with all GLP-1 receptor agonists, the rodent C-cell tumor risk applies to the GLP-1 agonist component. Long-term human data are not available for retatrutide.
• Lean mass loss: With weight loss of 24%, significant loss of lean body mass is expected, though body composition data from Phase 2 trials have not been fully reported.

Drug Interactions

Formal drug interaction studies for retatrutide have not been published as of April 2026. Based on the mechanism of action and class effects, the following interactions are anticipated:12

• Oral medications (class effect): Like other GLP-1 receptor agonists, retatrutide is expected to slow gastric emptying, which may affect the absorption kinetics of concomitantly administered oral medications. Particular caution is warranted with narrow-therapeutic-index drugs (warfarin, levothyroxine, digoxin).
• Insulin and sulfonylureas: Concurrent use may increase the risk of hypoglycemia. In the Phase 2 diabetes trial, dose adjustments of background medications were permitted at investigator discretion.2
• Other incretin-based therapies: Co-administration with other GLP-1 receptor agonists, GIP receptor agonists, or dual agonists has not been studied and should be avoided due to overlapping mechanisms and potential for additive adverse effects.
• Hepatically metabolized drugs: The glucagon receptor agonist component may affect hepatic enzyme activity. Formal CYP interaction studies are pending.

Storage & Handling

• Clinical trial supply: Retatrutide for clinical trial use was stored under refrigerated conditions (36–46°F / 2–8°C) per trial protocols.
• Commercial formulation: Not available. Storage and handling specifications for a commercial product will be established upon regulatory approval.
• General peptide handling: As a peptide-based injectable, retatrutide is expected to require protection from light, avoidance of freezing, and refrigerated storage prior to use. Do not use if the solution appears cloudy, discolored, or contains particles.

Legal & Regulatory Status

• United States (FDA): Not approved. Retatrutide is an investigational new drug (IND) currently in Phase 3 clinical trials (TRIUMPH program). No NDA has been submitted as of April 2026.5
• European Union (EMA): Not approved. No marketing authorization application has been submitted.
• Clinical trial access: Retatrutide is available only through enrollment in Eli Lilly-sponsored clinical trials registered on ClinicalTrials.gov.
• Manufacturer: Eli Lilly and Company (Indianapolis, Indiana, USA).
• Illicit market warning: Any retatrutide available outside of clinical trials is not a legitimate pharmaceutical product, is not subject to quality control, and may pose serious safety risks. Purchasing or using such products is strongly discouraged and may be illegal.

Open Questions

Retatrutide represents a novel mechanism with limited clinical data. Numerous important questions remain:

• Phase 3 confirmation: The Phase 2 results are unprecedented, but Phase 3 trials with larger sample sizes and longer follow-up are essential to confirm the efficacy and safety signals. The TRIUMPH program results will be critical for regulatory evaluation.5
• Cardiovascular outcomes: No cardiovascular outcomes trial (CVOT) has been completed or initiated for retatrutide. Whether the weight loss and metabolic improvements translate into reduced cardiovascular events remains unknown.
• Long-term safety of glucagon agonism: Chronic glucagon receptor activation raises theoretical concerns about hepatic glycogen depletion, amino acid wasting, and effects on bone metabolism. These will require long-term monitoring.4
• Body composition and lean mass: With weight loss exceeding 20%, the proportion of lean mass lost is a critical clinical concern. Strategies for lean mass preservation (resistance training, protein intake targets) need formal evaluation.
• Weight regain after discontinuation: Whether the dramatic weight loss achieved with retatrutide can be maintained after treatment cessation, or whether indefinite therapy will be required, is unknown.
• Comparative positioning: Head-to-head trials comparing retatrutide with tirzepatide and semaglutide would clarify the relative risk-benefit profiles, but such trials have not been announced as of April 2026.6